Portal de Periódicos da CAPES

Are BMI and Negative Hormone Receptors Prognostic Factors in HER2+ Early-stage Breast Cancer?

2020; Elsevier BV; Volume: 20; Issue: 4 Linguagem: Inglês

10.1016/j.clbc.2020.01.010

1938-0666

Roberta Maltoni, Michela Palleschi, Mattia Altini, Ilaria Massa, William Balzi, Sara Ravaioli, Maria Maddalena Tumedei, Andrea Rocca, Sara Bravaccini,

Breast Cancer Treatment Studies

We read the recently reported article by Cantini et al. 1 Cantini L. Pistelli M. Merloni F. et al. Body mass index and hormone receptor status influence recurrence risk in HER2-positive early breast cancer patients. Clin Breast Cancer. 2020; 20: e89-e98 Abstract Full Text Full Text PDF PubMed Scopus (5) Google Scholar They had retrospectively analyzed the role of the body mass index (BMI) and hormone receptor (HR) status in 238 patients with human epidermal growth factor receptor 2-positive (HER2+) early-stage breast cancer (BC). 1 Cantini L. Pistelli M. Merloni F. et al. Body mass index and hormone receptor status influence recurrence risk in HER2-positive early breast cancer patients. Clin Breast Cancer. 2020; 20: e89-e98 Abstract Full Text Full Text PDF PubMed Scopus (5) Google Scholar The patients had received chemotherapy and trastuzumab (Herceptin) for 1 year. 1 Cantini L. Pistelli M. Merloni F. et al. Body mass index and hormone receptor status influence recurrence risk in HER2-positive early breast cancer patients. Clin Breast Cancer. 2020; 20: e89-e98 Abstract Full Text Full Text PDF PubMed Scopus (5) Google Scholar The authors reported a higher risk of relapse for patients with HR− status and BMI of ≥ 25 kg/m2. Although these results were very interesting, we would like to underline some points.